Related Experiment Videos

Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker

W J Brooks1, M F Jarvis, G C Wagner

  • 1Department of Psychology, Rutgers State University, New Brunswick, New Jersey.

Insights

Monoamine oxidase-B (MAO-B) converts MPTP into a toxic metabolite. Fluoxetine pretreatment prevented MPTP-induced dopamine and serotonin depletions, supporting extra-dopaminergic production of MPP+.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Monoamine oxidase-B (MAO-B) is implicated in converting MPTP to its toxic metabolite MPP+.
  • MAO-B is primarily localized in astrocytes and serotonergic neurons, suggesting extra-dopaminergic MPP+ production.

Purpose of the Study:

  • To investigate the site of MPP+ production following MPTP administration.
  • To determine if fluoxetine pretreatment affects MPTP-induced neurotoxicity.

Main Methods:

  • Systemic administration of MPTP.
  • Pretreatment with fluoxetine, a selective serotonin reuptake inhibitor.
  • Measurement of striatal dopamine and serotonin concentrations.

Main Results:

  • Fluoxetine pretreatment significantly attenuated MPTP-induced depletions of striatal dopamine.
  • Fluoxetine pretreatment also attenuated MPTP-induced depletions of striatal serotonin.
  • These findings support the hypothesis that MPP+ is produced outside dopaminergic neurons.

Conclusions:

  • MPP+ production occurs outside of dopaminergic neurons.
  • Astrocyte and serotonergic neuron MAO-B activity contributes to MPTP neurotoxicity.
  • Targeting extra-dopaminergic pathways may be a strategy for mitigating MPTP-induced damage.

Related Concept Videos